KalVista Pharmaceuticals (KALV) Non-Current Deffered Revenue (2014 - 2020)
KalVista Pharmaceuticals recorded quarterly Non-Current Deffered Revenue of $2.5 million in Q1 2020, down 9.22% quarter-over-quarter from $2.8 million in Q4 2019, and down 31.81% year-over-year from $3.7 million in Q1 2019.
KalVista Pharmaceuticals' Non-Current Deffered Revenue history runs 6 years deep, the most recent figure standing at $2.5 million for Q1 2020.
- In Q1 2020, Non-Current Deffered Revenue fell 31.81% year-over-year to $2.5 million; the TTM figure through Jan 2020 stood at $2.5 million (down 31.81% YoY), while the FY2019 annual figure was $3.3 million, down 69.23% from the prior year.
- Non-Current Deffered Revenue came in at $2.5 million for Q1 2020 at KalVista Pharmaceuticals, down from $2.8 million in the prior quarter.
- In the past five years, Non-Current Deffered Revenue ranged from a high of $13.9 million in Q1 2018 to a low of $49000.0 in Q1 2016.
- A 4-year average of $5.3 million and a median of $3.5 million in 2019 frame the typical range for Non-Current Deffered Revenue.
- Across the five-year window, Non-Current Deffered Revenue jumped 2350.0% in 2016 and sank 73.61% in 2019, its largest moves.
- KalVista Pharmaceuticals' Non-Current Deffered Revenue stood at $49000.0 in 2016, then jumped by 9430.61% to $4.7 million in 2018, then plunged by 41.03% to $2.8 million in 2019, then fell by 9.22% to $2.5 million in 2020.
- According to Business Quant data, Non-Current Deffered Revenue over the past three periods registered $2.5 million, $2.8 million, and $2.9 million for Q1 2020, Q4 2019, and Q3 2019 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 225.10 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | KalVista Pharmaceuticals | 1.44 Bn | 1.25 Bn | 56.41 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jan 31, 2020 | 2.50 Mn |
| Oct 31, 2019 | 2.75 Mn |
| Jul 31, 2019 | 2.87 Mn |
| Apr 30, 2019 | 3.34 Mn |
| Jan 31, 2019 | 3.67 Mn |
| Oct 31, 2018 | 4.67 Mn |
| Jul 31, 2018 | 8.47 Mn |
| Apr 30, 2018 | 10.86 Mn |
| Jan 31, 2018 | 13.89 Mn |
| Mar 31, 2016 | 49,000.00 |
| Dec 31, 2015 | 56,000.00 |
| Sep 30, 2015 | 64,000.00 |
| Jun 30, 2015 | 71,000.00 |
| Mar 31, 2015 | 2,000.00 |
| Dec 31, 2014 | 85,000.00 |